David Moatazedi Sells 6,251 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 6,251 shares of the company’s stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the sale, the insider now directly owns 508,619 shares in the company, valued at approximately $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Evolus Stock Performance

NASDAQ:EOLS opened at $12.05 on Friday. The stock has a 50 day simple moving average of $13.66 and a 200 day simple moving average of $13.79. The stock has a market cap of $766.22 million, a P/E ratio of -13.24 and a beta of 1.28. Evolus, Inc. has a 1-year low of $9.25 and a 1-year high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on EOLS. Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Evolus in a research note on Wednesday, March 5th. Barclays raised their price target on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Evolus in a report on Wednesday, March 5th.

Institutional Investors Weigh In On Evolus

A number of hedge funds and other institutional investors have recently modified their holdings of EOLS. KBC Group NV bought a new position in shares of Evolus during the fourth quarter worth approximately $49,000. IFP Advisors Inc lifted its position in shares of Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after acquiring an additional 4,709 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Evolus in the fourth quarter worth $106,000. Rafferty Asset Management LLC acquired a new position in Evolus in the fourth quarter valued at about $115,000. Finally, Quantbot Technologies LP bought a new stake in Evolus during the fourth quarter worth about $118,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.